2025 年第 8 期 第 20 卷

通心络胶囊联合增强型体外反搏对缺血性心肌病心力衰竭患者临床疗效研究

Clinical efficacy of Tongxinluo capsule combined with enhanced external counterpulsation in patients with ischemic cardiomyopathy and heart failure

作者：张爱爱1刘纬2杜美玲1李飞星1易梦阳1韩伟1宋建英1李方江1

英文作者：Zhang Aiai1 Liu Wei2 Du Meiling1 Li Feixing1 Yi Mengyang1 Han Wei1 Song Jianying1 Li Fangjiang1

单位：1河北北方学院附属第一医院心血管内科，张家口075000；2河北北方学院，张家口075000

英文单位：1Department of Cardiovascular Medicine the First Affiliated Hospital of Hebei North University Zhangjiakou 075000 China; 2Hebei North University Zhangjiakou 075000 China

关键词：缺血性心肌病心力衰竭；通心络胶囊；增强型体外反搏

英文关键词：Ischemiccardiomyopathyheartfailure;Tongxinluocapsule;Enhancedexternalcounterpulsation

• 摘要：

• 目的 评估通心络胶囊联合增强型体外反搏（EECP）在缺血性心肌病心力衰竭患者中的临床疗效。方法 选取2021年5月至2023年6月于河北北方学院附属第一医院心内科住院的缺血性心肌病心力衰竭患者188例，采用区组随机化法分为对照组和观察组，各94例。对照组给予常规西药联合EECP治疗，观察组在对照组基础上联合通心络胶囊治疗。2组均治疗8周。比较2组治疗前后中医证候评分、血流动力学指标（心排血量、心脏指数、每搏输出量）、心功能指标［左心室收缩末期内径（LVESD）、左心室射血分数（LVEF）、左心室舒张末期内径（LVEDD）］和安全性情况。结果 2组治疗8周时的中医证候评分均低于治疗前，且观察组低于对照组［（9.4±2.3）分比（11.7±2.8）分］（均P＜0.05）。2组治疗8周时的心排血量、心脏指数、每搏输出量均高于治疗前，且观察组均高于对照组（均P＜0.05）。2组患者治疗8周时的LVESD、LVEDD均低于治疗前，LVEF均高于治疗前，且观察组LVESD、LVEDD均低于对照组，LVEF高于对照组（均P＜0.05）。治疗与观察期间，2组恶心呕吐、失眠、腹部不适发生率比较，差异均无统计学意义（均P＞0.05）。结论  通心络胶囊联合EECP治疗缺血性心肌病心

  力衰竭患者，能改善中医证候评分、血流动力学和心功能指标，且安全性良好。

• Objective To evaluate the clinical efficacy of Tongxinluo capsule combined with enhanced external counterpulsation (EECP) in patients with ischemic cardiomyopathy and heart failure. Methods A total of 188 patients with ischemic cardiomyopathy and heart failure who were hospitalized in the Department of Cardiovascular Medicine, the First Affiliated Hospital of Hebei North University from May 2021 to June 2023 were selected. The patients were divided into control group and observation group by block randomization method, with 94 cases in each group. The control group was treated with conventional western medicine combined with EECP, and the observation group was treated with Tongxinluo capsule on the basis of the control group. Both groups were treated for 8 weeks. The traditional Chinese medicine syndrome scores, hemodynamic indicators (cardiac output, cardiac index, stroke volume), cardiac function indicators ［left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD)］, and safety were compared between the two groups before and after treatment. Results The traditional Chinese medicine syndrome scores of the two groups at 8 weeks of treatment were lower than those before treatment, and those of the observation group were lower than those of the control group ［(9.4±2.3) vs (11.7±2.8)］(all P＜0.05). The cardiac output, cardiac index and stroke volume of the two groups at 8 weeks of treatment were higher than those before treatment, and those of the observation group were higher than those of the control group (all P＜0.05). After 8 weeks of treatment, LVESD and LVEDD of the two groups were lower than those before treatment, and LVEF was higher than that before treatment, and LVESD and LVEDD of the observation group were lower than those of the control group, and LVEF was higher than that of the control group (all P＜0.05). During the treatment and observation period, there was no significant difference in the incidence of nausea and vomiting, insomnia, and abdominal discomfort between the two groups (all P＞0.05). Conclusion Tongxinluo capsule combined with EECP in the treatment of patients with ischemic cardiomyopathy and heart failure can improve the traditional Chinese medicine syndrome score, hemodynamics and cardiac function indexes, and has good safety.